Business model

I-Mab Reports Third Quarter 2024 Results

I-Mab Biopharma

Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient in randomized Phase 2 study ofuliledlimab in first-line mNSCLC in 1H 2025

Home Previous 65 66 67 68 69 70 71 Next Tail

10 Items Per Page (Page 68 / 142) Total 1419 Items